Related Experiment Video
Updated: May 22, 2025
07:58
Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
1.0K
Gliclazide loaded spanlastic nanovesicles: empowering bioavailability and antidiabetic efficacy
Shimaa Mazyed1, Soha M El-Masry1, Haidy Abbas1
1Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Drug Development and Industrial Pharmacy
|March 17, 2025
Summary
Spanlastics nanovesicles (SNVs) loaded with gliclazide (GCZ) improved oral bioavailability and anti-diabetic effects. The optimized SNVs demonstrated enhanced pharmacokinetic and pharmacodynamic profiles compared to free GCZ.
Area of Science:
- Pharmaceutical Sciences
- Nanotechnology
- Drug Delivery Systems
Background:
- Gliclazide (GCZ) is an oral anti-diabetic drug with limited bioavailability.
- Nanovesicular drug delivery systems offer potential to enhance drug efficacy.
Purpose of the Study:
- To formulate and characterize spanlastics nanovesicles (SNVs) loaded with gliclazide (GCZ).
- To evaluate the enhanced oral bioavailability and anti-diabetic effects of GCZ-loaded SNVs.
Main Methods:
- SNVs were prepared using the ethanol injection method with varying span and edge activator types.
- A 2³ factorial design optimized the formulation.
- In vitro drug release, in vivo pharmacokinetics, and pharmacodynamics were assessed.
Main Results:
- The optimized formulation (F6) exhibited spherical particles with high entrapment efficiency (95.1%).
- In vitro release showed sustained drug release over 4 hours.
- In vivo studies demonstrated significantly increased Cmax (12.93 ± 1.34) and improved glucose reduction (58.31% MR) compared to free GCZ.
Conclusions:
- GCZ-loaded SNVs significantly enhance oral bioavailability and anti-diabetic activity.
- The developed SNVs provide a promising approach for improving gliclazide therapy.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
01:24Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
01:23Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
01:05Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K